Showing results (1631-1640 of 1,663) with videos related to

Sort By:
Pageof 167
Nature Communications|January 3, 2023
The splanchnic mesenchyme is the tissue of origin for pancreatic fibroblasts during homeostasis and tumorigenesisLu Han, Yongxia Wu, Kun Fang, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|October 10, 2024
Discovery of Ketal-Ester Ionizable Lipid Nanoparticle with Reduced Hepatotoxicity, Enhanced Spleen Tropism for mRNA Vaccine DeliveryKai Lv, Zhenlei Yu, Jing Wang, et al.
Journal of Crohn'S & Colitis|February 8, 2020
Inhibition of Histone Deacetylation by MS-275 Alleviates Colitis by Activating the Vitamin D ReceptorChunxiao Li, Yi Chen, Huatuo Zhu, et al.
Nature Communications|February 24, 2021
Triptonide is a reversible non-hormonal male contraceptive agent in mice and non-human primatesZongliang Chang, Weibing Qin, Huili Zheng, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|March 12, 2022
PRMT5 regulates RNA m6A demethylation for doxorubicin sensitivity in breast cancerYing Wu, Zhe Wang, Lu Han, et al.
Nature Communications|December 14, 2023
Atherosclerotic plaque development in mice is enhanced by myeloid ZEB1 downregulationM C Martinez-Campanario, Marlies Cortés, Alazne Moreno-Lanceta, et al.
Cell Reports. Medicine|June 26, 2026
Multi-omics profiling unveils biological and clinical insights into pulmonary sarcomatoid carcinomaLiangdong Sun, Jue Wang, Yilv Yan, et al.
F1000Research|August 1, 2022
Protocol for a feasibility study of longitudinal surveys to assess the impact of policies on tobacco use among school-going adolescents in South AsiaMasuma Pervin Mishu, Kamran Siddiqi, Ann McNeill, et al.
Molecular Oncology|September 25, 2014
Volitinib, a potent and highly selective c-Met inhibitor, effectively blocks c-Met signaling and growth in c-MET amplified gastric cancer patient-derived tumor xenograft modelsPaul R Gavine, Yongxin Ren, Lu Han, et al.
Signal Transduction and Targeted Therapy|October 12, 2025
First-line treatment with chemotherapy, surufatinib (an angio-immuno kinase inhibitor), and camrelizumab (an anti-PD-1 antibody) for locally advanced or metastatic pancreatic ductal adenocarcinoma: a phase Ib/II randomized studyRu Jia, Hai-Yan Si, Meng-Jiao Fan, et al.
Pageof 167